Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NTLA-3001 in AATD-Associated Lung Disease
NCT06622668Phase 2Withdrawn
- Sponsor
- Intellia Therapeutics
- Start
- Nov 2024
- Primary completion
- Jan 2025
- Modality
- Gene Silencing, CRISPR-Cas9, Gene Addition/Replacement
- Countries
- 1
01
Overview
A Phase 2 trial of NTLA-3001 in alpha-1 antitrypsin deficiency (AATD), sponsored by Intellia Therapeutics. Planned start Nov 2024; status: withdrawn.
02
Drugs
NTLA-3001
03
Conditions
alpha-1 antitrypsin deficiency (AATD)
Beyond the preview
Go deeper on NCT06622668.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06622668.